Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3404-3411

  Anderson, Richard A ^a   Rosendahl, Mikkel ^b   Kelsey, Thomas W ^c   Cameron, David A ^d,e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Amenorrhoea; AMH; Breast cancer; Chemotherapy; Fertility; Ovarian reserve

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; INHIBIN B; METHOTREXATE; MUELLERIAN INHIBITING FACTOR;

ADULT; AMENORRHEA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; OVARIAN RESERVE; OVARY FUNCTION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

AMENORRHOEA; AMH; BREAST CANCER; CHEMOTHERAPY; FERTILITY; OVARIAN RESERVE;

ADULT; AMENORRHEA; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; DENMARK; DOWN-REGULATION; EARLY DETECTION OF CANCER; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; INHIBINS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; OVARY; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885182696     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.014     Document Type: Article

References (39)

1. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
2. J. Byrne, T.R. Fears, and M.H. Gail Early menopause in long-term survivors of cancer during adolescence Am J Obstet Gynecol 166 1992 788 793
3. J. Bines, D.M. Oleske, and M.A. Cobleigh Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol 14 1996 1718 1729
4. J.A. Petrek, M.J. Naughton, and L.D. Case Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study J Clin Oncol 24 2006 1045 1051
5. D. Meirow, H. Biederman, R.A. Anderson, and W.H.B. Wallace Toxicity of chemotherapy and radiation on female reproduction Clin Obstet Gynecol 53 2010 727 739
6. S. Morgan, R.A. Anderson, C. Gourley, W.H. Wallace, and N. Spears How do chemotherapeutic agents damage the ovary? Hum Reprod Update 18 2012 525 535
7. M. Berliere, F. Dalenc, and N. Malingret Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel BMC Cancer 8 2008 56
8. S.M. Swain, J.H. Jeong, and C.E. Geyer Jr. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer N Engl J Med 362 2010 2053 2065
9. M. Rosendahl, J. Ahlgren, and J. Andersen The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study Eur J Cancer 45 2009 3198 3204
10. M.J. Faddy, R.G. Gosden, A. Gougeon, S.J. Richardson, and J.F. Nelson Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause Hum Reprod 7 1992 1342 1346
11. W.H. Wallace, and T.W. Kelsey Human ovarian reserve from conception to the menopause PLoS One 5 2010 e8772
12. I.A.J. van Rooij, F.J.M. Broekmans, and G.J. Scheffer Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study Fertil Steril 83 2005 979 987
13. F.J. Broekmans, J. Kwee, D.J. Hendriks, B.W. Mol, and C.B. Lambalk A systematic review of tests predicting ovarian reserve and IVF outcome Hum Reprod Update 12 2006 685 718
14. E.W. Freeman, M.D. Sammel, H. Lin, and C.R. Gracia Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women J Clin Endocrinol Metab 97 2012 1673 1680
15. R.A. Anderson, S.M. Nelson, and W.H. Wallace Measuring anti-Mullerian hormone for the assessment of ovarian reserve: When and for whom is it indicated? Maturitas 71 2012 28 33
16. G.E. Hale, and H.G. Burger Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause Best Pract Res Clin Obstet Gynaecol 23 2009 7 23
17. A. La Marca, S. Malmusi, and S. Giulini Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation Hum Reprod 19 2004 2738 2741
18. R.A. Anderson, A.P.N. Themmen, and A. Al Qahtani The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer Human Reprod 21 2006 2583 2592
19. J.G. Bentzen, J.L. Forman, and A. Pinborg Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception Reprod Biomed Online 25 2012 612 619
20. K. Jayaprakasan, B. Campbell, J. Hopkisson, I. Johnson, and N. Raine-Fenning A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation Fertil Steril 93 2010 855 864
21. L.E. Bath, W.H. Wallace, M.P. Shaw, C. Fitzpatrick, and R.A. Anderson Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound Hum Reprod 18 2003 2368 2374
22. S. Lie Fong, P.J. Lugtenburg, and I. Schipper Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies Hum Reprod 23 2008 674 678
23. H.I. Su, M.D. Sammel, and J. Green Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors Cancer 116 2010 592 599
24. C.R. Gracia, M.D. Sammel, and E. Freeman Impact of cancer therapies on ovarian reserve Fertil Steril 97 2012 134 140
25. K. Lutchman Singh, S. Muttukrishna, and R.C. Stein Predictors of ovarian reserve in young women with breast cancer Br J Cancer 96 2007 1808 1816
26. C. Anders, P.K. Marcom, and B. Peterson A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer Cancer Invest 26 2008 286 295
27. R.A. Anderson, and D.A. Cameron Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer J Clin Endocrinol Metab 96 2011 1336 1343
28. B. Yu, N. Douglas, and M.J. Ferin Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy Cancer 116 2010 2099 2105
29. A.M. Wallace, S.A. Faye, R. Fleming, and S.M. Nelson A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II) Ann Clin Biochem 48 2011 370 373
30. L.K. Zeltzer, E. Chen, and R. Weiss Comparison of psychologic outcome in adult survivors of childhood acute lymphoblastic leukemia versus sibling controls: a cooperative Children's Cancer Group and National Institutes of Health study J Clin Oncol 15 1997 547 556
31. P. Canney, R. Coleman, and J. Morden TACT2 trial in early breast cancer (EBC): Differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019) Eur J Cancer 48 Suppl. 1 2012 S102
32. L. Rokach, and O. Maimon Top-down induction of decision trees classifiers-a survey IEEE Trans Syst Man Cybern B Cybern 35 2005 476 487
33. S.J. Lee, L.R. Schover, and A.H. Partridge American Society of Clinical Oncology recommendations on fertility preservation in cancer patients J Clin Oncol 24 2006 2917 2931
34. J.M. Letourneau, E.E. Ebbel, and P.P. Katz Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer Cancer. 118 2012 1710 1717
35. T.W. Kelsey, P. Wright, S.M. Nelson, R.A. Anderson, and W.H. Wallace A validated model of serum anti-Müllerian hormone from conception to menopause PLoS One 6 2011 e22024
36. S. Lie Fong, J.S. Laven, and F.G. Hakvoort-Cammel Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone Hum Reprod 24 2009 982 990
37. M. Rosendahl, C.Y. Andersen, and N. La Cour Freiesleben Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age Fertil Steril 94 2010 156 166
38. C. Decanter, F. Morschhauser, and P. Pigny Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results Reprod Biomed Online 20 2010 280 285
39. M.F. Brougham, P.M. Crofton, and E.J. Johnson Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study J Clin Endocrinol Metab 97 2012 2059 2067